Stop Reporting Results? The NIH’s "Get Out of Jail Free" Card

Send us Fan Mail

 The NIH just dropped a regulatory bombshell: Notice NOT-OD-26-032. Effectively immediately, Basic Experimental Studies in Humans (BESH) are no longer classified as "Clinical Trials" for reporting purposes. Is this a victory for common sense, or an administrative "fudge" to hide years of academic non-compliance? In this episode, Darshan Kulkarni breaks down why this "Great Reset" changes the mathematics of due diligence, tech transfer, and company valuations. If you are licensing university tech, your "human clinical data" might have just been downgraded to "well-funded experiment." 

Support the show

www.kulkarnilawfirm.com

Episode Transcript

Darshan (00:00):
If you're an academic researcher, you know that for
the last decade the phraseclinical trial has been the bane
of your existence.
I mean red tape.
Massive reporting hurdles.
And for many of you, theconstant fear of public shaming
on clinicaltrials.gov.
Only because you didn't want toreport results for study that
you viewed as basic science.

(00:20):
Heck, I know some science andthis would go, I didn't even
know the rule was different.
I thought this was the rule.
Well, the NIH just handed you aget out of jail free card.
Notice NOT OD26032.
Look that one up.
NOT OD 26032.
They dropped that on January 29,2026, and it's kind of

(00:43):
important.
The NIH has decided that basicexperimental studies in humans.
Basic experimental studies andhumans are no longer clinical
trials.
Now, is this a victory forcommon sense, or is it a
strategic move to fudge thenumbers and hide years of
academic noncompliance?

(01:03):
Today we're peeling back thelayers in this great reset.
Before we dive, do me a favor.
Hit that subscribe button.
Tackle the intersection of food,drugs, and research law every
week, and you don't want to missthe next deep dive into the
regulations that actually runyour lab.
Now let's get into it.
Some of you may be askingDarshan, why are you so fired up

(01:24):
about a policy notice?
So my background is a bitunique.
I'm a pharmacist, but I'm also afood and drug lawyer.
I spend my days helpingcompanies navigate the FDA and
more importantly, helpingsponsors do due diligence when
they want to license technologyfrom the university.
When a company looks at yourtech, they aren't just looking
at your Western blossom or yourp-values, they're looking at
your compliance record.

(01:45):
And I'm the guy who tells themthat your record is clean or if
it's a regulatory mess.
Today I'm gonna tell you why theNIH update changes the
mathematics for you and foreveryone else.
Let's be real.
Large academic sites have lookedbad for a very, very long time.
Advocacy groups have beenranking universities on their
failure to report studies foryears.
Best studies were the biggestreason for those F grades.

(02:07):
Why?
Because you didn't think that astudy on how the brain reacts to
light was a clinical trial.
But the NIH did.
By issuing this notice, the NIHis effectively doing an N run.
They've decided that thousandsof studies that were
non-compliant should never havebeen on the scoreboard in the
first place.
Starting May 25th, 2026, theBESH exemption from

(02:29):
clinicaltrials.gov is official.
It's a massive administrativefudge that makes the university
compliance numbers look waybetter overnight.

SPEAKER_00 (02:41):
Enjoying our content?
We'd love to hear more.
Please like, comment, share, andfind more.

Darshan (02:49):
But as a sponsor, I see it for what it is.
It's a reset of the goalposts.
The administrative tail of yourtechnology just got shorter,
which is great for speed.
It doesn't change the fact thatthe data was once in a
regulatory gray zone.
Now, this is where it getstricky for my tech transfer
friends.
You like to use the term humanclinical data to inflate the

(03:10):
price of a license.
The NIH now defines a clinicaltrial only as something that has
the potential for directadvancement of health.
BESH is now officiallyfundamental biology.
If I'm a sponsor, I'm using thisnotice as leverage.
If your clinical data isactually BESH data, it may not

(03:30):
carry the regulatory weight orthe proof of concept validation
that my investors expect from atrue phase one or phase two
trial.
Now don't conflate human subjectresearch with clinical trial.
One is a true value inflectionpoint, the other is just a
well-funded experiment.
Now, sponsors, listen up.
The reclassification creates anew line in the sand.

(03:52):
The NIH is expiring allBESH-specific funding
opportunities.
Going forward, these studieswill flow through the clinical
trial not allowed channels.
But what if a researcheractually misclassifies a study?
If they call it BESH to avoidthe red tape, but it was
actually intended to informadvances in health.

(04:13):
You've got a major problem whenyou try to file that IMD with
the FDA.
Your regulatory dossier willhave a mismatch.
And don't forget the NIH's datamanagement and sharing policy.
Even if it's not a clinicaltrial, the data sharing
requirements still apply.
The fundamental know-how mightstill be accessible to the
public faster than you think.

(04:34):
You need to check the notice ofaward for every grant that
touched the tech.
Now, what's the bottom line?
Bottom line, honestly, it's awin for reducing paperwork,
which is probably a good thing,right?
But is it a huge win for thosewho are trying to spin out the
company or license an asset?
DNI just moved the goalposts tohelp academics look better on
paper.
My job is to make sure you seewhat's actually on the field.

(04:59):
Want me to review your currentBESH protocols or your tech
transfer portfolio to see howthis great reset impacts your
valuation before May 2026?
Find me at the Kilcarney LawFirm.
Just go towww.kilcarneylawfirm.com or look
for me on LinkedIn.
And don't forget to subscribe tothe KLF Deep Dive.
I'm going to give you moreinsights that the university PR

(05:21):
department is probably not goingto tell you.
I'm Darshan Kilkarni.
Thanks for listening.
Call, click, or email.